1. Home /
  2. Healthcare

Healthcare

How Reinventing the Lab Coat Can Empower the Minds of Tomorrow

How Reinventing the Lab Coat Can Empower the Minds of Tomorrow

Here's how a project--such as reinventing the lab coat--can empower the minds of tomorrow.

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.

Why Actions Speak Louder Than Words When It Comes to Equality

Why Actions Speak Louder Than Words When It Comes to Equality

Equality in the workplace matters.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Checking Up on 5 Favorite Healthcare REITs

Checking Up on 5 Favorite Healthcare REITs

This group benefits from two trends -- declining interest rates and an aging of the population.

Select Medical Holdings Could Soon Resume Its Long-Term Uptrend

Select Medical Holdings Could Soon Resume Its Long-Term Uptrend

Let's review the charts of SEM.

Elanco to Buy Bayer's Animal Health Business for $7.6 Billion

Elanco to Buy Bayer's Animal Health Business for $7.6 Billion

Elanco says the deal, which is subject to approval from regulators, would double the size of its companion animal business.

Medtronic Rises as Heart Device Maker Pumps Out Revenue Beat

Medtronic Rises as Heart Device Maker Pumps Out Revenue Beat

Medtronic's cardiac and vascular unit generates $2.79 billion in fiscal first-quarter revenue, surpassing analysts' estimates.

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.